Porphyria News and Research

RSS

AMT announces full year 2009 results; reports modest decrease in operating expenses

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.

24 Feb 2010

Recent clinical trials in patients with ALBP show that SOMA 250 mg reduces disability

A recent analysis of two pivotal clinical trials in patients with acute low back pain (ALBP) who were treated with SOMA® (carisoprodol) 250 mg showed significantly improved functionality and reduced disability after three days of treatment, as measured by the Roland-Morris Disability Questionnaire (RMDQ).

4 Feb 2010

AMT reaches another milestone in the official marketing authorisation process for Glybera

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, has reached another important milestone in the official marketing authorisation process for its lead product Glybera(R), AMT's proprietary product for lipoprotein lipase deficiency (LPLD).

25 Jan 2010

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD).

6 Jan 2010

Novartis presents 6-month results from its EVEREST study for PCV

QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.

9 Dec 2009

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.

18 Nov 2009

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Relying on an independent study by the Institute of Medicine (IOM), Secretary of Veterans Affairs Eric K. Shinseki decided to establish a service-connection for Vietnam Veterans with three specific illnesses based on the latest evidence of an association with the herbicides referred to as Agent Orange.

15 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

Treatment for acute intermittent porphyria

The Center for Applied Medical Research (CIMA) from the University of Navarra and the Amsterdam Molecular Therapeutics BV (AMT) have demonstrated the pre-clinical effectiveness of a treatment against acute intermittent porphyria.

2 Apr 2007

Molecular missing link between fasting and acute attacks of porphyria

A team of researchers has discovered a molecular missing link that helps explain why fasting brings on acute attacks of the genetic disease hepatic porphyria, according to a new report in the 26 August issue of the journal Cell.

29 Aug 2005

Arsenic caused the madness of King George III

According to a newly released study, high concentrations of arsenic have been found in a sample of King George III's hair, and this, say the authors, may have contributed to his unusually severe and prolonged bouts of madness.

23 Jul 2005

Arsenic in King George III's hair contributed to bouts of madness

A study revealing high concentrations of arsenic in a sample of King George III’s hair is published in this week’s issue of The Lancet. The authors believe the presence of arsenic in the King’s hair contributed to his unusually severe and prolonged bouts of madness.

21 Jul 2005